Siamformet

Each tablet contains Metfomin (dimethylbiguanide) hydrochloride 500 mg, 850 mg.

Pharmacology: SIAMFORMET is an oral hypoglycemic agent which: Lowers elevated blood glucose level to normal. It has no effect on the blood sugar in healthy individuals; Does not stimulate the β cells of the pancreas to produce further insulin, but enables diabetic patients to make use of the available endogenous insulin; Is not metabolized. It is mostly excreted unchanged in the urine, and a small fraction excreted in the faeces.

Initial therapy for newly diagnosed maturity-onset diabetics.
Concurrent therapy with a sulphonylurea is indicated for patients whose blood glucose level cannot be controlled by either metformin or sulfonylurea alone.
Adjuvant therapy in insulin-dependent diabetics to reduce the dosage of insulin required.

SIAMFORMET should be taken with meals, 1-2 tablets once or twice a day, or as directed by the physicians. In concurrent therapy with either a sulphonylurea or insulin, blood glucose level should be checked, due to the possibility of hypoglycemia.
Initially, the dosage should be 1-2 tablets once or twice a day. Dosage should be gradually increased up to 4 tablets a day until diabetic control is obtained, then dosage reduction is possible.
When administered with a sulfonylurea, the initial dosage for SIAMFORMET is 1 tablet a day. The dosage of SIAMFORMET should be gradually increased until diabetic control is obtained. The dosage of sulfonylurea may then be reduced or even withdrawn, and SIAMFORMET can be continued as a sole therapy.
Administering with insulin: 1. When the dosage of insulin is less than 60 units a day, 1 tablet should be added initially, followed by gradual reduction of the insulin (4 units every 2-4 days).
2. When the dosage of insulin is more than 60 units a day, the addition of SIAMFORMET may cause a rapid reduction of blood glucose level. Close monitoring of patients is advised in the first 24 hours after the addition of SIAMFORMET. After this period, the recommendations in 1 should be followed.

Patients with liver diseases.
Patients with severe renal diseases.
Patients with cardiac failure, myocardial infarction.
Patients with alcoholism.
Patients with diabetic coma and ketoacidosis from the accumulation of ketone bodies.
Pregnant women.

This medicine should be taken as directed by physician only. Should symptoms of dizziness or fainting occur, consult a physician immediately.

Antidiabetic Agents

A10BA02 - metformin ; Belongs to the class of biguanides. Used in the treatment of diabetes.

D